SNAP: Switching Nucleoside Analogues Protocol - Lipoatrophy and Mitochondrial Function

Completed

Conditions studied: HIV Infection

In brief

HIV infected subjects receiving antiretroviral treatment for greater than 6 years with be evaluated for clinical lipoatrophy and mitochondrial function after switching nucleoside analogues from stavudine (d4T) to tenofovir treatment and after 4. Hypothesis: Tenofovir therapy will increase peripheral fat content as assessed by DEXA and mitochondrial function at 48 weeks.

Key facts

Study ID

NCT00225082

Run by

Northwestern University

People needed

12

Starts

2004-11-01

Expected to finish

2007-10-01

Last updated by the study team

2010-10-05

Who can join

Age: any. Sex: any. Healthy volunteers: not accepted.

You may qualify if…

• HIV infection
• Receiving Kaletra, stavudine, and lamivudine for greater than 6 years (through Abbott M97-720 study)
• Planning to switch from stavudine to tenofovir

You may not qualify if…

• Will continue to receive stavudine

Where it is running

• Northwestern University — Chicago, Illinois, United States

Full record on ClinicalTrials.gov

Trial information comes from ClinicalTrials.gov and is refreshed daily. TrialsForMe does not provide medical care and does not run the studies it lists.